192 related articles for article (PubMed ID: 29516490)
1. The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome.
Moore JN; Gastonguay MR; Ng CM; Adeniyi-Jones SC; Moody DE; Fang WB; Ehrlich ME; Kraft WK
Clin Pharmacol Ther; 2018 Jun; 103(6):1029-1037. PubMed ID: 29516490
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.
Ng CM; Dombrowsky E; Lin H; Erlich ME; Moody DE; Barrett JS; Kraft WK
Pharmacotherapy; 2015 Jul; 35(7):670-80. PubMed ID: 26172282
[TBL] [Abstract][Full Text] [Related]
3. Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches.
McPhail BT; Emoto C; Butler D; Fukuda T; Akinbi H; Vinks AA
J Clin Pharmacol; 2021 Jul; 61(7):857-870. PubMed ID: 33382111
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine in Neonatal Abstinence Syndrome.
Kraft WK
Clin Pharmacol Ther; 2018 Jan; 103(1):112-119. PubMed ID: 29105752
[TBL] [Abstract][Full Text] [Related]
5. Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome.
Winhusen T; Wilder C; Wexelblatt SL; Theobald J; Hall ES; Lewis D; Van Hook J; Marcotte M
Contemp Clin Trials; 2014 Sep; 39(1):158-65. PubMed ID: 25183042
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.
Jones HE; Johnson RE; Jasinski DR; O'Grady KE; Chisholm CA; Choo RE; Crocetti M; Dudas R; Harrow C; Huestis MA; Jansson LM; Lantz M; Lester BM; Milio L
Drug Alcohol Depend; 2005 Jul; 79(1):1-10. PubMed ID: 15943939
[TBL] [Abstract][Full Text] [Related]
7. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial.
Kraft WK; Gibson E; Dysart K; Damle VS; Larusso JL; Greenspan JS; Moody DE; Kaltenbach K; Ehrlich ME
Pediatrics; 2008 Sep; 122(3):e601-7. PubMed ID: 18694901
[TBL] [Abstract][Full Text] [Related]
8. Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome.
Mizuno T; McPhail BT; Kamatkar S; Wexelblatt S; Ward L; Christians U; Akinbi HT; Vinks AA
Clin Pharmacokinet; 2021 Feb; 60(2):249-259. PubMed ID: 32939690
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy for Neonatal Abstinence Syndrome: Choosing the Right Opioid or No Opioid at All.
McPherson C
Neonatal Netw; 2016; 35(5):314-20. PubMed ID: 27636696
[TBL] [Abstract][Full Text] [Related]
10. Management of neonatal abstinence syndrome in neonates born to opioid maintained women.
Ebner N; Rohrmeister K; Winklbaur B; Baewert A; Jagsch R; Peternell A; Thau K; Fischer G
Drug Alcohol Depend; 2007 Mar; 87(2-3):131-8. PubMed ID: 17000060
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics.
van Hoogdalem MW; McPhail BT; Hahn D; Wexelblatt SL; Akinbi HT; Vinks AA; Mizuno T
Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):87-103. PubMed ID: 33049155
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Population Pharmacokinetics of Morphine in Neonates With Abstinence Syndrome After Oral Administration of Diluted Tincture of Opium.
Liu T; Lewis T; Gauda E; Gobburu J; Ivaturi V
J Clin Pharmacol; 2016 Aug; 56(8):1009-18. PubMed ID: 26712409
[TBL] [Abstract][Full Text] [Related]
13. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
Kraft WK; Dysart K; Greenspan JS; Gibson E; Kaltenbach K; Ehrlich ME
Addiction; 2011 Mar; 106(3):574-80. PubMed ID: 20925688
[TBL] [Abstract][Full Text] [Related]
14. Finding the right treatment for neonatal abstinence syndrome: is this the right time?
Yen E; Davis JM
J Perinatol; 2018 Jul; 38(7):785-787. PubMed ID: 29515226
[TBL] [Abstract][Full Text] [Related]
15. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome.
Kahila H; Saisto T; Kivitie-Kallio S; Haukkamaa M; Halmesmäki E
Acta Obstet Gynecol Scand; 2007; 86(2):185-90. PubMed ID: 17364281
[TBL] [Abstract][Full Text] [Related]
16. Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome.
van Hoogdalem MW; Johnson TN; McPhail BT; Kamatkar S; Wexelblatt SL; Ward LP; Christians U; Akinbi HT; Vinks AA; Mizuno T
Clin Pharmacol Ther; 2022 Feb; 111(2):496-508. PubMed ID: 34679189
[TBL] [Abstract][Full Text] [Related]
17. [Neonatal seizures, buprenorphine abstinence syndrome, and substitutive treatment with morphine].
Dahan S; Elefant E; Girard I; Azcona B; Champion V; Mitanchez D
Arch Pediatr; 2011 Mar; 18(3):287-90. PubMed ID: 21269813
[TBL] [Abstract][Full Text] [Related]
18. Breastfeeding promotion for management of neonatal abstinence syndrome.
Pritham UA
J Obstet Gynecol Neonatal Nurs; 2013; 42(5):517-26. PubMed ID: 24020477
[TBL] [Abstract][Full Text] [Related]
19. Maternal buprenorphine treatment and infant outcome.
Jansson LM; Velez ML; McConnell K; Spencer N; Tuten M; Jones H; Rios R; King VL; Gandotra N; Millio L; DiPietro JA
Drug Alcohol Depend; 2017 Nov; 180():56-61. PubMed ID: 28869859
[TBL] [Abstract][Full Text] [Related]
20. Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial.
Brown MS; Hayes MJ; Thornton LM
J Perinatol; 2015 Apr; 35(4):278-83. PubMed ID: 25357093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
